… may up-regulate PD-L1 expression in tumor cells, 20-22 which is a predictive … to durvalumab,
we hypothesized that durvalumab would provide clinical benefit after chemoradiotherapy. …

… durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned
to durvalumab … 33.1% of patients randomly assigned to durvalumab remain alive and free of …

… PFS after CCRT treatment in patients with stage III non-squamous cell lung cancer was 8.9–…
with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network), …

… Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer … Regarding
consolidation treatment of unresectable stage III NSCLC after chemo-radiotherapy, a phase III …

… , stage III non-small-cell lung cancer is poor. Although use of durvalumab after concurrent
chemoradiotherapy … and to show that durvalumab does not result in worse PROs than placebo. …

… therapy were durable but those with placebo were not. If consolidation treatment with
durvalumab after chemoradiotherapy improves OS, even in resectable stage IIIA patients, the …

… Two patients discontinued durvalumab after completing 26 infusions and restarted …
durvalumab after CRT as the standard of care for patients with unresectable stage III NSCLC. …

… durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy. An
estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), …

… help restore systemic and long-term immune response after chemoradiotherapy. … durvalumab
in patients with stage III, unresectable NSCLC who did not have disease progression after …

… -world study of durvalumab use after chemoradiation in stage III non–small cell lung cancer.
… use of the PD-L1 inhibitor durvalumab after concurrent CRT in patients with unresectable …